ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer.

Am J Clin Oncol

*Dana-Farber Cancer Institute/Brigham and Women's Hospital †Harvard Radiation Oncology Program, Boston, MA ‡Department of Urology, University of Alabama at Birmingham School of Medicine, Birmingham, AL §American Urological Association, Linthicum, MD ∥Joint Center for Radiation Therapy, Boston, MA ¶American Society of Clinical Oncology, Alexandria, VA #MD Anderson Cancer Center, Houston, TX **Department of Radiation Oncology, University of California San Francisco, San Francisco ∥∥Radiologic Associates of Sacramento and Sutter Cancer Center, Sacramento ##Western Radiation Oncology, Mountain View Oncology, Mountain View, CA ††William Beaumont Hospital, Troy ‡‡Department of Radiation Oncology, University of Michigan, Novi, MI §§Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV ¶¶Department of Radiation Oncology, University of Virginia, Charlottesville, VA ***Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA †††Memorial Sloan Kettering Cancer Center, New York, NY ‡‡‡Mayo Clinic, Rochester, MN.

Published: June 2014

Purpose: To present the most updated American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of external-beam radiation to manage stage T1 and T2 prostate cancer.

Methods: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Results: The panel summarized the most recent and relevant literature on the topic and voted on 3 clinical variants illustrating the appropriate dose, techniques, and use of adjuvant hormone therapy with external-beam radiation for low-risk, intermediate-risk, and high-risk prostate cancer. Numerical rating and commentary reflecting the panel consensus was given for each treatment approach in each variant.

Conclusions: External-beam radiation is a key component of the curative management of T1 and T2 prostate cancer. By combining the most recent medical literature and expert opinion, this guideline can aid clinicians in the appropriate use of external-beam radiation for prostate cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000049DOI Listing

Publication Analysis

Top Keywords

prostate cancer
16
external-beam radiation
16
stage prostate
8
american college
8
college radiology
8
expert panel
8
appropriate external-beam
8
medical literature
8
expert opinion
8
external-beam
5

Similar Publications

Introduction: Prostate cancer (PCa) is the commonest urologic cancer worldwide and the leading cause of male cancer deaths in Nigeria. In Nigeria, orchidectomy remains the primary androgen deprivation therapy. Dihydrotestosterone (DHT) is the active prostatic androgen, but its relationship with PCa severity has not been extensively studied in Africa.

View Article and Find Full Text PDF

We intended to investigate the potential of several transitional zone (TZ) volume-related variables for the detection of clinically significant prostate cancer (csPCa) among lesions scored as Prostate Imaging Reporting and Data System (PI-RADS) category 3. Between September 2018 and August 2023, patients who underwent mpMRI examination and scored as PI-RADS 3 were queried from our institution. The diagnostic performances of prostate-specific antigen density (PSAD), TZ-adjusted PSAD (TZPSAD), and TZ-ratio (TZ volume/whole gland prostate volume) were analyzed.

View Article and Find Full Text PDF

Introduction: In NCCN favorable intermediate-risk (FIR) prostate cancer (PCa) patients treated with radical prostatectomy (RP), we tested the effect of upstaging and upgrading on cancer-specific mortality (CSM).

Methods: Within the SEER database (2010-2021), upstaging (≥pT3a or pN1) and upgrading (ISUP ≥3) rates in FIR RP patients were tabulated. Kaplan-Meier (KM) plots and multivariable Cox-regression models (CRMs) were fitted.

View Article and Find Full Text PDF

Dosimetric comparison of CyberKnife and conventional linac prostate SBRT plans: analysis of the PACE-B Study.

Int J Radiat Oncol Biol Phys

January 2025

The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK; Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK.

Purpose: In the PACE-B study, a non-randomised comparison of toxicity outcomes between stereotactic body radiotherapy (SBRT) platforms revealed fewer urinary side-effects with CyberKnife (CK) compared to conventional linac (CL) SBRT. This analysis compares baseline characteristics and planning dosimetry between the CK-SBRT and CL-SBRT cohorts in PACE-B, aiming to provide insight into possible reasons for differing toxicity outcomes between the platforms.

Methods: Dosimetric parameters for the surrogate urethra (SU), contoured urethra, bladder, bladder trigone (BT), and rectum were extracted from available CT planning scans of PACE-B SBRT patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!